Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS

Naval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, Mark Brandt, Sherry Pierce, Kenneth Vaughan, Jing Ning, Graciela M. Nogueras González, Keyur Patel, Jeff Jorgensen, Naveen Pemmaraju, Tapan Kadia, Marina Konopleva, Michael Andreeff, Courtney DiNardo, Jorge Cortes, Renee Ward, Adam Craig, and Farhad Ravandi

Disclosures: RELEVANT CONFLICT OF INTEREST DISCLOSURE This study was supported by a grant from Sunesis. ND and FR have received research funding from Sunesis. ND, HK, and FR have received honoraria from Sunesis.

Contributions: ND, FR and HK designed and conducted the trial. ND and FR reviewed the data and wrote the first draft. ND, HK, GGM, EJ, GB, NP, TK, MK, MA, CD, JC, and FR treated the patients. SP, KV, JN, RW, AC, and GG collected the data and performed the statistics. All authors participated in the discussion, have reviewed and commented on the drafts and approved the final manuscript.